Natural leukocyte interferon-alpha therapy in patients with chronic granulocytic leukemia who have antibody-mediated resistance to treatment with recombinant interferon-alpha.

作者信息

Tefferi A, Grendahl D C

机构信息

Division of Hematology and Internal Medicine, Pharmacy, Mayo Clinic, Rochester, MN 55905, USA.

出版信息

Am J Hematol. 1996 Jul;52(3):231-3. doi: 10.1002/(SICI)1096-8652(199607)52:3<231::AID-AJH20>3.0.CO;2-H.

Two patients with chronic-phase chronic granulocytic leukemia initially responded to recombinant interferon alpha-2a (rIFN-alpha-2a) but relapsed as a result of development of hightiter neutralizing antibodies to rIFN-alpha-2a. Both patients were subsequently treated with natural leukocyte IFN-alpha (IFN-alpha-n3), and one of the two patients achieved a durable second hematologic and cytogenetic remission. IFN-alpha-n3 may be considered for patients in whom antibody-mediated resistance to rIFN-alpha-2a develops.